Altimmune, Inc. (ALT) stock
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.65+0.03 (+2.17%)
Close on Nov 13, 2026Market cap $319.98MP/E –Yield –
Altimmune r&d expenses
Research and development expenses are spending on new products and technology.
Altimmune's R&D Expenses for the twelve months ending Sep 30, 2026 was $80.27M, up 18.4% year over year. For fiscal 2025 it was $66.43M, down 19.2% from the year before. Over ten years it grew 29.2% a year on average. The highest annual figure on record is $82.23M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.43M | -19.2% |
| FY2024 | Dec 31, 2024 | $82.23M | +25.0% |
| FY2023 | Dec 31, 2023 | $65.80M | -6.7% |
| FY2022 | Dec 31, 2022 | $70.54M | -5.4% |
| FY2021 | Dec 31, 2021 | $74.54M | +49.8% |
| FY2020 | Dec 31, 2020 | $49.77M | +180.2% |
| FY2019 | Dec 31, 2019 | $17.77M | -3.8% |
| FY2018 | Dec 31, 2018 | $18.46M | +0.3% |
| FY2017 | Dec 31, 2017 | $18.41M | +154.9% |
| FY2016 | Dec 31, 2016 | $7.22M | +40.7% |
| FY2015 | Dec 31, 2015 | $5.13M | -44.9% |
| FY2014 | Dec 31, 2014 | $9.32M | -39.0% |
| FY2013 | Dec 31, 2013 | $15.29M | -21.6% |
| FY2012 | Dec 31, 2012 | $19.51M | -8.1% |
| FY2011 | Dec 31, 2011 | $21.22M | +1.6% |
| FY2010 | Dec 31, 2010 | $20.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $27.02M | +80.6% |
| Q2 FY2026 | Jun 30, 2026 | $18.66M | +8.2% |
| Q1 FY2026 | Mar 31, 2026 | $16.19M | +2.3% |
| Q4 FY2025 | Dec 31, 2025 | $18.41M | -6.9% |
| Q3 FY2025 | Sep 30, 2025 | $14.96M | -24.5% |
| Q2 FY2025 | Jun 30, 2025 | $17.24M | -18.5% |
| Q1 FY2025 | Mar 31, 2025 | $15.83M | -26.3% |
| Q4 FY2024 | Dec 31, 2024 | $19.78M | +17.0% |
| Q3 FY2024 | Sep 30, 2024 | $19.80M | +7.7% |
| Q2 FY2024 | Jun 30, 2024 | $21.16M | +59.6% |
| Q1 FY2024 | Mar 31, 2024 | $21.49M | +24.6% |
| Q4 FY2023 | Dec 31, 2023 | $16.91M | -11.8% |
| Q3 FY2023 | Sep 30, 2023 | $18.39M | -9.2% |
| Q2 FY2023 | Jun 30, 2023 | $13.25M | -17.1% |
| Q1 FY2023 | Mar 31, 2023 | $17.25M | +14.2% |
| Q4 FY2022 | Dec 31, 2022 | $19.18M | -5.0% |
| Q3 FY2022 | Sep 30, 2022 | $20.26M | -30.6% |
| Q2 FY2022 | Jun 30, 2022 | $15.99M | +20.5% |
| Q1 FY2022 | Mar 31, 2022 | $15.10M | +27.2% |
| Q4 FY2021 | Dec 31, 2021 | $20.19M | +125.5% |
| Q3 FY2021 | Sep 30, 2021 | $29.21M | +71.4% |
| Q2 FY2021 | Jun 30, 2021 | $13.27M | -20.0% |
| Q1 FY2021 | Mar 31, 2021 | $11.88M | +65.3% |
| Q4 FY2020 | Dec 31, 2020 | $8.95M | +211.5% |
| Q3 FY2020 | Sep 30, 2020 | $17.04M | +95.2% |
| Q2 FY2020 | Jun 30, 2020 | $16.59M | +463.5% |
| Q1 FY2020 | Mar 31, 2020 | $7.19M | +123.4% |
| Q4 FY2019 | Dec 31, 2019 | $2.87M | -6.3% |
| Q3 FY2019 | Sep 30, 2019 | $8.73M | +84.6% |
| Q2 FY2019 | Jun 30, 2019 | $2.95M | -40.1% |
| Q1 FY2019 | Mar 31, 2019 | $3.22M | -44.0% |
| Q4 FY2018 | Dec 31, 2018 | $3.06M | -31.3% |
| Q3 FY2018 | Sep 30, 2018 | $4.73M | -19.9% |
| Q2 FY2018 | Jun 30, 2018 | $4.92M | -6.4% |
| Q1 FY2018 | Mar 31, 2018 | $5.75M | +106.3% |
| Q4 FY2017 | Dec 31, 2017 | $4.46M | +87.7% |
| Q3 FY2017 | Sep 30, 2017 | $5.91M | – |
| Q2 FY2017 | Jun 30, 2017 | $5.25M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.79M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.38M | – |
See a number that looks wrong?